Luxiana Biotech

Luxiana Biotech develops oligonucleotide therapeutics for multiple diseases, leveraging cross-linked modified nucleic acid (XNA) technology licensed from Osaka University. The company's proprietary cross-linked modified nucleic acids bind strongly to target mRNA, achieving high efficacy while reducing hepatotoxicity risk, resulting in enhanced safety profiles compared to conventional nucleic acid therapeutics. The technology also offers potential for changing the delivery target of nucleic acid drugs beyond the liver and kidneys, where they typically accumulate. Luxiana Biotech operates across four business segments: co-creation drug discovery with pharmaceutical companies, XNA technology licensing, in-house drug discovery, and XNA monomer supply. The company can create antisense designs incorporating cross-linked modified nucleic acids, expanding the therapeutic potential of oligonucleotide-based treatments. Based on nucleic acid chemistry technology accumulated at Osaka University, the company is dedicated to practicalizing safe and effective nucleic acid therapeutics to contribute to healthcare for patients fighting diseases. The company actively presents at industry conferences including the Japanese Society for Nucleic Acid Medicines and global startup pitch events. Founded in 2017 and headquartered in Suita, Osaka, Japan, Luxiana Biotech has raised $7.6M in Series C funding from investors including JFC, Nissan Chemical, Summit Pharmaceuticals, Mizuho Capital, Daiwa Corporate Investment, Osaka University Venture Capital, and Kansai Mirai Bank.